Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy

New England Journal of Medicine

Volumn 341, Issue 5, 1999, Pages 312-318

  Kern, Winfried V ^a   Cometta, Alain ^b   De Bock, Robrecht ^c   Langenaeken, John ^d   Paesmans, Marianne ^d   Gaya, Harold ^e   Zanetti, Giorgio ^b   Calandra, Thierry ^b   Glauscr, Michel P ^b   Crokaert, Françoise ^d   Klastersky, Jean ^d   Skoutelis, Athanasios ^f   Bassaris, Harry ^f   Zinner, Stephen H ^g   Viscoli, Claudio ^h   Engelhard, Dan ⁱ   Padmos, Andrew ^j  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c All gemeen Ziekenhuis Middelheim   (Belgium)

^d JULES BORDET INSTITUTE   (Belgium)

^e ROYAL BROMPTON HOSPITAL   (United Kingdom)

^f UNIVERSITY HOSPITAL OF PATRAS   (Greece)

^g BROWN UNIVERSITY   (United States)

^h UNIVERSITY OF GENOA   (Italy)

ⁱ HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^j Kingston Regional Cancer Center   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTINEOPLASTIC AGENT; CEFTRIAXONE; CIPROFLOXACIN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADOLESCENT; ADULT; AGED; ANTIMICROBIAL THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CATHETER INFECTION; CHILD; CLINICAL TRIAL; DIARRHEA; DRUG COST; DRUG EFFICACY; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; GRANULOCYTOPENIA; HUMAN; HYPOKALEMIA; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEPHROTOXICITY; ORAL DRUG ADMINISTRATION; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; RISK FACTOR; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AGRANULOCYTOSIS; AMIKACIN; AMOXICILLIN; ANTINEOPLASTIC AGENTS; BACTEREMIA; CEFTRIAXONE; CHILD; CHILD, PRESCHOOL; CIPROFLOXACIN; CLAVULANIC ACID; DRUG THERAPY, COMBINATION; FEMALE; FEVER; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 0033614926     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199907293410502     Document Type: Article

References (39)

1. Hughes WT, Armstrong D, Bodey GP, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 1990;161:381-96. [Erratum, J Infect Dis 1990;161:1316.]
2. Hughes WT, Armstrong D, Bodey GP, et al. 1997 Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clin Infect Dis 1997;25:551-73.
3. Bodey GP, Buckley M, Sathe YS, Freircich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966;64:328-40.
4. Rubin MM, Hathorn JW, Pizzo PA. Controversies in the management of febrile neutropenic cancer patients. Cancer Invest 1988;6:167-84.
5. Rolston KVI, Berkey P, Bodey GP, et al. A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. Arch Intern Med 1992;152:283-91.
6. Cometta A, Zinner S, de Bock R, et al. Piperacillin/tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother 1995;39:445-52.
7. Elting LS, Rubenstein EB, Rolston KVI, Bodey GP. Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis 1997;25:247-59.
8. Talcott JA, Siegel RD, Finbcrg R, Goldman L. Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol 1992;10:316-22.
9. Hann I, Viscoli C, Paesmans M, Gaya H, Glauser M. A comparison of outcome from febrile neutropenic episodes in children compared with adults: results from four EORTC studies. Br J Haematol 1997;99:580-8.
10. Rossini F, Pioltelli P, Mingozzi S, et al. Amikacin and ceftazidime as empirical antibiotic therapy in severely neutropenic patients: analysis of prognostic factors. Support Care Cancer 1994;2:259-65.
11. Lucas KG, Brown AE, Armstrong D, Chapman D, Heller G. The identification of febrile, neutropenic children with neoplastic disease at low risk for bacteremia and complications of sepsis. Cancer 1996;77:791-8.
12. Meropol NJ, Fox KR, Vaughn DJ, Zeiber N. A pilot study of early hospital discharge in adult patients with fever and neutropenia. Eur J Cancer 1994;30A:1595-6.
13. Mullen CA, Buchanan GR. Early hospital discharge of children with cancer treated for fever and neutropenia: identification and management of the low-risk patient. J Clin Oncol 1990;8:1998-2004.
14. Bash RO, Katz JA, Cash JV, Buchanan GR. Safety and cost effectiveness of early hospital discharge of lower risk children with cancer admitted for fever and neutropenia. Cancer 1994;74:189-96.
15. Horowitz HW, Holmgren D, Seiter K Stepdown single agent antibiotic therapy for the management of the high risk neutropenic adult with hematologic malignancies. Leuk Lymphoma 1996;23:159-63.
16. Gardembas-Pain M, Desablens B, Sensebe L, Lamy T, Ghandour C, Boasson M. Home treatment of febrile neutropenia: an empirical oral antibiotic regimen. Ann Oncol 1991;2:485-7.
17. Malik IA, Abbas Z, Karim M. Randomised comparison of oral ofloxacin alone with combination of parenteral antibiotics in neutropenic febrile patients. Lancet 1992;339:1092-6.
18. Rubcnstcin EB, Rolston K, Benjamin RS, et al. Outpatient treatment of febrile episodes on low-risk neutropenic patients with cancer. Cancer 1993;71:3640-6.
19. Velasco E, Costa MA, Martins CA, Nucci M. Randomized trial comparing oral ciprofloxacin plus penicillin V with amikacin plus carbenicillin or ceftazidime for empirical treatment of febrile neutropenic cancer patients. Am J Clin Oncol 1995;18:429-35.
20. Hidalgo M, Hornedo J, Lumbreras C, et al. Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever: a prospective, randomized clinical trial. Cancer 1999;85:213-9.
21. Shah A, Lettieri J, Kaiser L, Echols R, Heller AH. Comparative pharmacokinctics and safety of ciprofloxacin 400 mg i.v. thrice daily versus 750 mg po twice daily. J Antimicrob Chemother 1994;33:795-801.
22. Catchpole C, Andrews JM, Woodcock J, Wise R. The comparative pharmacokinetics and tissue penetration of single-dose ciprofloxacin 400 mg i.v. and 750 mg po. J Antimicrob Chemother 1994;33:103-10.
23. Meunier F, Zinner SH, Gaya H, et al. Prospective randomized evaluation of ciprofloxacin versus piperacillin plus amikacin for empiric antibiotic therapy of febrile granulocytopenic cancer patients with lymphomas and solid tumors. Antimicrob Agents Chemother 1991;35:873-8.
24. Lim SH, Smith MP, Goldstonc AH, Machin SJ. A randomized prospective study of ceftazidime and ciprofloxacin with or without teicoplanin as an empiric antibiotic regimen for febrile neutropenic patients. Br J Haematol 1990;76:Suppl 2:41-4.
25. Ball P, Geddes A, Rolinson G. Amoxicillin clavulanate: an assessment after 15 years of clinical application. J Chemother 1997;9:167-98.
26. The EORTC International Antimicrobial Therapy Cooperative Group. Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann Intern Med 1993;119:584-93.
27. Cometta A, Calandra T, Gaya H, et al. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother 1996;40:1108-15.
28. Makuch R, Simon R. Sample size requirements for evaluating a conservative therapy. Cancer Treat Rep 1978;62:1037-40.
29. Monitoring trial progress. In: Pocock SJ. Clinical trials: a practical approach. Chichester, England: John Wiley, 1983:142-59.
30. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979;35:549-56.
31. De Mets DL, Lan KK. Interim analysis: the alpha spending function approach. Stat Med 1994;13:1341-52.
32. Lan KK, De Mets DL. Changing frequency of interim analysis in sequential monitoring. Biometrics 1989;45:1017-20.
33. Lan KK, Zucker DM. Sequential monitoring of clinical trials: the role of information and Brownian motion. Stat Med 1993;12:753-65.
34. Dunnett CW, Gent W. Significance testing to establish equivalence between treatments, with special reference to data in the form of 2×2 tables. Biometrics 1977;33:593-602.
35. Brunier H, Whitehead J. PEST 3 (planning and evaluation of sequential trials) operating manual. Reading, England: University of Reading, 1993.
36. Talcott JA, Whalen A, Clark J, Rieker PP, Finberg R. Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction rule. J Clin Oncol 1994;12:107-14.
37. Malik IA, Khan WA, Karim M, Aziz Z, Khan A. Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: results of a prospective randomized trial. Am J Med 1995;98:224-31.
38. Kern WV, Andriof W, Oethinger M, Kern P, Hacker J, Marre R. Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center. Antimicrob Agents Chemother 1994;38:681-7.
39. Cometta A, Calandra T, Bille J, Glauser MP. Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia. N Engl J Med 1994;330:1240-1.